News | December 07, 2021
Study shows Glaxo-Vir drug works against Omicron mutations
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The hospital is scheduled to open in 2024 with a bed capacity of 225
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The fund aims at investing in companies that extends human healthspan
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
Subscribe To Our Newsletter & Stay Updated
